Opinion

Video

ASCO 2024: Key Findings of the LAURA Trial on7:19 Osimertinib for EGFR-Mutated NSCLC

Author(s):

Jason Porter, MD

Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.

Video content above is prompted by the following questions:

  • Discuss the data that was presented at the 2024 ASCO Annual Meeting on the progression-free survival from the phase 3 trial LAURA of osimertinib in patients with unresectable stage III EGFR-mutated NSCLC without progression after definitive CRT.
  • What are your key takeaways from this study and how will it impact the current standard of care for EGFR-mutated NSCLC?
Related Videos
Ticiana Leal, MD
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Ana Baramidze, MD, PhD
Ticiana Leal, MD, Emory Winship Cancer Institute
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Related Content
FDA | Image Credit: © Artur-stock.adobe.com
November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

Ashling Wahner
The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).
Lung cancer | Image Credit: © Crystal light - stock.adobe.com
November 15th 2024

Tailored Management Needed for Male Patients With NSCLC After Surgery

Maggie L. Shaw
Lung cancer is the top cause of cancer-related death worldwide.
Lung cancer image | Image Credit: © appledesign-stock.adobe.com
November 8th 2024

Sunvozertinib NDA Submitted to FDA for NSCLC

Chris Ryan
A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer (NSCLC).
Biomarker Scrabble tiles | Image Credit: © lexiconimages-stock.adobe.com
October 30th 2024

Improving Early-Stage Lung Cancer Care

Maggie L. Shaw
More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.
Martin Dietrich, MD, PhD
October 24th 2024

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

Maggie L. Shaw
Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Umit Tapan, MD, Boston Medical Center
October 18th 2024

Expanding Access to NSCLC Innovations: Challenges and Opportunities

Maggie L. Shaw
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo